Maggie  Yuen net worth and biography

Maggie Yuen Biography and Net Worth

CFO of Penumbra

Maggie joined Penumbra in 2019, serving as Chief Financial Officer. Prior to Penumbra, Maggie spent more than 20 years of progressive leadership experience driving scalable finance organizations, processes and infrastructure in the manufacturing, medical devices, and life science industries. She most recently served as Vice President of Finance of the Genetic Science Division within Thermo Fisher Scientific, Inc., a business focused on instrument platforms, cloud-based software, content and services. In her role, she directed finance operations, strategic planning and business development activities, among a number of other executive functions. Prior to Thermo Fisher, Maggie held leadership positions with increasing responsibility at Mirion Technologies, and senior finance roles at Boston Scientific, Glu Mobile, and Johnson & Johnson. Maggie has also served on the Board of Directors of AtriCure, Inc. since June 2021. She received an MAcc and MBA from the Weatherhead School of Management and a BS from Case Western Reserve University.

What is Maggie Yuen's net worth?

The estimated net worth of Maggie Yuen is at least $4.06 million as of March 3rd, 2025. Yuen owns 15,243 shares of Penumbra stock worth more than $4,062,412 as of March 13th. This net worth estimate does not reflect any other investments that Yuen may own. Additionally, Yuen receives a salary of $666,040.00 as CFO at Penumbra. Learn More about Maggie Yuen's net worth.

How old is Maggie Yuen?

Yuen is currently 52 years old. There are 3 older executives and no younger executives at Penumbra. Learn More on Maggie Yuen's age.

What is Maggie Yuen's salary?

As the CFO of Penumbra, Inc., Yuen earns $666,040.00 per year. Learn More on Maggie Yuen's salary.

How do I contact Maggie Yuen?

The corporate mailing address for Yuen and other Penumbra executives is One Penumbra Place, Alameda CA, 94502. Penumbra can also be reached via phone at (510) 748-3200 and via email at investors@penumbrainc.com. Learn More on Maggie Yuen's contact information.

Has Maggie Yuen been buying or selling shares of Penumbra?

During the past quarter, Maggie Yuen has sold $572,000.00 in shares of Penumbra stock. Most recently, Maggie Yuen sold 2,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $286.00, for a transaction totalling $572,000.00. Following the completion of the sale, the chief financial officer now directly owns 15,243 shares of the company's stock, valued at $4,359,498. Learn More on Maggie Yuen's trading history.

Who are Penumbra's active insiders?

Penumbra's insider roster includes Arani Bose (Insider), Adam Elsesser (President, Chairman and CEO), Harpreet Grewal (Director), Don Kassing (Director), Bridget O'Rourke (Director), James Pray (Insider), Johanna Roberts (EVP), Surbhi Sarna (Director), Lambert Shiu (CAO), Thomas Wilder (Director), and Maggie Yuen (CFO). Learn More on Penumbra's active insiders.

Are insiders buying or selling shares of Penumbra?

In the last twelve months, insiders at the sold shares 28 times. They sold a total of 165,678 shares worth more than $39,988,786.76. The most recent insider tranaction occured on March, 5th when CEO Adam Elsesser sold 61,600 shares worth more than $17,469,144.00. Insiders at Penumbra own 5.0% of the company. Learn More about insider trades at Penumbra.

Information on this page was last updated on 3/5/2025.

Maggie Yuen Insider Trading History at Penumbra

See Full Table

Maggie Yuen Buying and Selling Activity at Penumbra

This chart shows Maggie Yuen's buying and selling at Penumbra by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$572ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$400k-$200k$0$200k$400kTotal Insider BuyingTotal Insider Selling

Penumbra Company Overview

Penumbra logo
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $260.12
Low: $256.54
High: $266.93

50 Day Range

MA: $268.84
Low: $236.12
High: $303.55

2 Week Range

Now: $260.12
Low: $148.00
High: $310.00

Volume

90,793 shs

Average Volume

396,356 shs

Market Capitalization

$10.02 billion

P/E Ratio

768.12

Dividend Yield

N/A

Beta

0.51